PENTETIC ACID

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H23N3O10
Molecular Weight	393.3465
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O

InChI

InChIKey=QPCDCPDFJACHGM-UHFFFAOYSA-N

InChI=1S/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)

HIDE SMILES / InChI

Molecular Formula	C14H23N3O10
Molecular Weight	393.3465
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/18830865 | https://www.truthinaging.com/ingredients/pentasodium-pentetate
Curator's Comment: description was created based on several sources, including: https://www.federalregister.gov/articles/2011/08/19/2011-21227/determination-that-pentetate-calcium-trisodium-trisodium-calcium-diethylenetriaminepentaacetate

on as chelating agents in cosmetics. Pentasodium Pentetate is readily soluble in water, but the corresponding free acid is not. Pentasodium Pentetate is used in almost 400 cosmetic products over a wide range of product categories, although it is mostly used in hair dyes and colors at use concentrations of 0.1% to 1.0%. Pentetic Acid and Pentasodium Pentetate inactivate metallic ions, such as calcium and magnesium, to maintain stability and appearance of cosmetic products. The inactivation of other metallic ions such as iron or copper also helps to prevent the oxidative deterioration of cosmetics and personal care products.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Metallic ions 7 Target ID: Metallic ions Sources: https://www.ncbi.nlm.nih.gov/pubmed/18830865	Chelating Agent 139
Radioactive metals 7 Target ID: CHEMBL2366037 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Chelating Agent 139

Conditions

Condition	Modality	Highest Phase	Product
Acne 100 Sources: https://www.drugs.com/otc/110273/dermaklear-akne-treatment-with-sulfur.html	Inactive ingredient	Approved 8583	DermaKlear Akne Treatment with Sulfur Approved Use Uses for the treatment of acne. Dries acne blemishes and allows skin to heal. Helps prevent new acne blemishes from forming. Launch Date 1940
Contamination with plutonium, americium, or curium 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Diagnostic	Withdrawn	PENTETATE CALCIUM TRISODIUM Approved Use Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. Launch Date 2004
Internal contamination with plutonium, americium, or curium 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021751s008lbl.pdf	Palliative	Approved 8583	PENTETATE ZINC TRISODIUM Approved Use Pentetate zinc trisodium injection is a radiomitigation chelator indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
1.6 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16257469/	29.4 μmol/kg single, intravenous dose: 29.4 μmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PENTETIC ACID plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.007 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16257469/	29.4 μmol/kg single, intravenous dose: 29.4 μmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PENTETIC ACID plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16257469/	29.4 μmol/kg single, intravenous dose: 29.4 μmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PENTETIC ACID plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.5 g 1 times / day multiple, subcutaneous Dose: 0.5 g, 1 times / day Route: subcutaneous Route: multiple Dose: 0.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2923478	unhealthy, 5-20 years) Health Status: unhealthy Age Group: 5-20 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2923478	Sources: https://pubmed.ncbi.nlm.nih.gov/2923478
4 g 1 times / day multiple, intramuscular Overdose Dose: 4 g, 1 times / day Route: intramuscular Route: multiple Dose: 4 g, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	Other AEs: Hemochromatosis... Other AEs: Hemochromatosis (grade 5, 3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf

AEs

AE	Significance	Dose	Population
Hemochromatosis	grade 5, 3 patients	4 g 1 times / day multiple, intramuscular Overdose Dose: 4 g, 1 times / day Route: intramuscular Route: multiple Dose: 4 g, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:35739	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:35739
ChemicalBook	CB5303977	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5303977
eMolecules	497513	https://www.emolecules.com/cgi-bin/more?vid=497513
MolPort	MolPort-002-324-582	https://www.molport.com/shop/molecule-link/MolPort-002-324-582
ZINC	ZINC000019419017	http://zinc15.docking.org/substances/ZINC000019419017

PubMed

Title	Date	PubMed
Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine.	2001-08-10	11371573
Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice.	2001-08	11454945
Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI.	2001-07-19	11459464
Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains.	2001-07-19	11459459
Lanthanide chemistry with (bis[[bis(carboxymethyl)amino]methyl]phosphinate: what does an extra phosphinate group do to EDTA?	2001-07-16	11442371
Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64).	2001-07-01	11431325
The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes.	2001-07-01	11395251
Chelated metal ions for therapeutic and diagnostic applications.	2001-07	11444098
Somatostatin receptor imaging: current status and future perspectives.	2001-07	11438628
Buttock granulomas: a consequence of intramuscular injection of Sandostatin detected by In-111 octreoscan.	2001-07	11416760
Detection of cerebrospinal fluid leak by dual-isotope spect with In-111 DTPA and Tc-99m HMDP.	2001-07	11416747
Effects of peroxynitrite on the reactivity of diabetic rat aorta.	2001-07	11408833
Zinc-induced activation of the human cytomegalovirus major immediate-early promoter is mediated by metallothionein and nuclear factor-kappaB.	2001-06-15	11437636
Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.	2001-06-01	11389078
Fluorometric determination of EDTA and EGTA using terbium-salicylate complex.	2001-06-01	11373087
In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection.	2001-06	11440037
Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy.	2001-06	11431601
The use of a modified technique to reduce radioactive air contamination in aerosol lung ventilation imaging.	2001-06	11430516
Early responses to nonconjugated polyribosylribitol phosphate challenge as evidence of immune memory after combined diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b primary vaccination.	2001-06	11419500
A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran.	2001-06	11390562
Scintigraphy and Doppler ultrasonography for the evaluation of obstructive urinary calculi.	2001-06	11378662
Biodegradability of ethylenediamine-based complexing agents.	2001-06	11337848
Oxidation of metal-diethylenetriaminepentaacetate (DTPA)--complexes during drinking water ozonation.	2001-06	11337832
Quantitative assays of the amount of diethylenetriaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry.	2001-05-17	11353534
Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents.	2001-05-15	11355857
Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111)In-DTPA-JIC 2DL.	2001-05-15	11341788
Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.	2001-05-14	11348721
[Should school children receive pertussis vaccine?].	2001-05-10	11449768
Magnetic resonance imaging of a benign Brenner tumor with an ipsilateral simple cyst.	2001-05	11409485
Significance of (111)In-DTPA chelate in renal radioactivity levels of (111)In-DTPA-conjugated peptides.	2001-05	11395320
Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides.	2001-05	11395314
Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs.	2001-05	11394361
Relationships between chromium biomagnification ratio, accumulation factor, and mycorrhizae in plants growing on tannery effluent-polluted soil.	2001-05	11392761
Contrast agents in acute myocardial infarction.	2001-05	11390263
Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In.	2001-05	11388583
Direct MR arthrography of plica synovialis mediopatellaris.	2001-05	11350286
Dysprosium-bearing red cells as potential transverse relaxation agents for MRI.	2001-05	11323820
Synthesis, characterization, and relaxivity of two linear Gd(DTPA)-polymer conjugates.	2001-04-21	11312677
Decomposition of beta-alaninediacetic acid and diethylenetriamine-pentaacetic acid by hydrogen peroxide in alkaline conditions.	2001-04-01	11348070
Blood-pool scintigraphic diagnosis of fractured lumbar vertebral hemangioma.	2001-04	11392297
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.	2001-04	11385960
Mechanism of lipid peroxidation photosensitized by tiaprofenic acid: product studies using linoleic acid and 1,4-cyclohexadienes as model substrates.	2001-04	11332030
Diethylenetriaminopentaacetic acid is unsuitable for long-term preservation of RBCs.	2001-04	11316910
Multi-level disruption of the spinal nerve root sleeves in spontaneous spinal cerebrospinal fluid leakage--two case reports.	2001-03	11372561
The kinetics and mechanisms of the reactions of aluminium(III) with gallic acid, gallic acid methyl ester and adrenaline.	2001-03	11330467
Metal chelators inhibit S-nitrosation of Cys beta 93 in oxyhemoglobin.	2001-02-28	11456789
Inhibitors of advanced glycation end product-associated protein cross-linking.	2001-02-14	11341999
Bilaminar pattern of tibial condyle cartilage layer on the fat-suppressed 3D gradient echo images: artifact or structural and biochemical difference in composition of cartilage?	2001-02	11358656
Towards the characterisation of heavy metals in dredged canal sediments and an appreciation of 'availability': two examples from the UK.	2001	11428147
Cancer chemopreventive activities of S-3-1, a synthetic derivative of danshinone.	2001	11355772

Patents

Sample Use Guides

In Vivo Use Guide

Adults and Adolescents: A single 1.0 gram initial dose of Ca-DTPA administered intravenously Pediatrics (less than 12 years of age): A single initial dose of 14 mg/kg administered intravenously not exceed 1.0 gram.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:52:21 GMT 2025` Edited by `admin` on `Wed Apr 02 08:52:21 GMT 2025`
Record UNII	7A314HQM0I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PENTETIC ACID

Official Name

English

PENTETATE

Preferred Name

English

DIETHYLENETRIAMINE PENTAACETIC ACID

Systematic Name

English

PENTETIC ACID [USP MONOGRAPH]

Common Name

English

PENTETIC ACID [MART.]

Common Name

English

PENTETIC ACID [MI]

Common Name

English

DIETHYLENE TRIAMINE PENTAACETIC ACID

Common Name

English

DIETHYLENETRIAMINE- N,N,N',N',N''-PENTAACETIC ACID

Common Name

English

NANODTPA

Brand Name

English

NANO-DTPA CAPSULE COMPONENT DTPA

Brand Name

English

pentetic acid [INN]

Common Name

English

DIETHYLENETRIAMINEPENTAACETATE

Common Name

English

NSC-7340

Code

English

DTPA

Code

English

NANODTPA COMPONENT DTPA

Brand Name

English

GLYCINE, N,N-BIS(2-(BIS(CARBOXYMETHYL)AMINO)ETHYL)-

Systematic Name

English

PENTETIC ACID [II]

Common Name

English

PENTETIC ACID [USP-RS]

Common Name

English

Pentetic acid [WHO-DD]

Common Name

English

NANODTPA ZN-DTPA COMPONENT DTPA

Brand Name

English

DTP-A

Code

English

PENTETIC ACID [USAN]

Common Name

English

PENTETATE [VANDF]

Common Name

English

DIETHYLENETRIAMINE PENTAACETIC ACID [VANDF]

Common Name

English

DIETHYLENETRIAMINEPENTAACETIC ACID

Common Name

English

PENTETIC ACID [VANDF]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

180203